SCHEMBL7038517

SCHEMBL7038517

NC(=O)c1ccnc(-c2cc(C(N)=O)ccn2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5C P41229 6/20 0.69
KDM4B O94953 3/20 0.69
KDM5B Q9UGL1 3/20 0.69
KDM2A Q9Y2K7 4/20 0.53
KDM3A Q9Y4C1 4/20 0.53
KDM4A O75164 4/20 0.53
KDM4E B2RXH2 4/20 0.53
KDM6B O15054 3/20 0.53
KDM4C Q9H3R0 3/20 0.53
P4HA1 P13674 1/20 0.52
MAP4K4 O95819 1/20 0.49
PARP1 P09874 6/20 0.48
JMJD6 Q6NYC1 1/20 0.47
MKNK1 Q9BUB5 1/20 0.47
MKNK2 Q9HBH9 1/20 0.47
F7 P08709 1/20 0.47
F3 P13726 1/20 0.47
SARM1 Q6SZW1 1/20 0.47
SIRT2 Q8IXJ6 1/20 0.47
SIRT6 Q8N6T7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18231524 0.92 KDM5C (0.66) KDM5CKDM4BKDM5BKDM2AKDM3A
SCHEMBL902063 0.89 KDM4E (0.72) KDM5CKDM4BKDM5BKDM2AKDM3A
SCHEMBL946431 0.85 ASIC3 (0.55) KDM5CKDM4BKDM5BKDM2AKDM3A
SCHEMBL1592852 0.85 KDM4B (0.58) KDM5CKDM4BKDM5BKDM2AKDM3A
SCHEMBL16033613 0.84 KDM5C (0.54) KDM5CKDM4BKDM5BKDM2AKDM3A
SCHEMBL28907344 0.83 KDM4B (0.56) KDM5CKDM4BKDM5BKDM2AKDM3A
SCHEMBL29932888 0.83 MAP4K4 (0.55) KDM5CKDM4BKDM5BMAP4K4PARP1
SCHEMBL31635775 0.82 KDM4C (0.75) KDM5CKDM4BKDM5BKDM2AKDM3A
SCHEMBL31582735 0.82 KDM5C (0.55) KDM5CKDM4BKDM5BKDM2AKDM3A
SCHEMBL1758188 0.82 MAP4K4 (0.57) KDM5CKDM4BKDM5BKDM2AKDM3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612415-B2 Stereoselective process for preparing substituted polycyclic pyridone SHIONOGI & CO., LTD. (JP) 2026-04-28 US disclosed
EP-3693373-B1 STEREOSELECTIVE PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES SHIONOGI & CO (JP) 2025-11-26 EP disclosed
CN-111386276-B Stereoselective process for preparing substituted polycyclic pyridone derivatives 盐野义制药株式会社 2023-06-23 CN disclosed
US-20230040262-A1 STEREOSELECTIVE PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2023-02-09 US disclosed
US-11286262-B2 Stereoselective process for preparing substituted polycyclic pyridone derivatives SHIONOGI & CO., LTD. (JP) 2022-03-29 US disclosed
EP-3693373-A1 METHOD FOR STEREOSELECTIVELY PRODUCING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVE Shionogi&Co., Ltd. (JP) 2020-08-12 EP disclosed
US-20200247818-A1 STEREOSELECTIVE PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2020-08-06 US disclosed
WO-2003055477-A1 METHOD FOR THE TREATMENT OF MC RECEPTOR RELATED DISORDERS WITH A CHELATE AND/OR A CHELATOR 7TM PHARMA A/S (DK) 2003-07-10 WO disclosed
WO-2003003008-A1 CHEMICAL LIBRARIES USEFUL FOR DRUG DISCOVERY PROCESSES 7TM PHARMA A/S (DK) 2003-01-09 WO disclosed
WO-2003003009-A1 USE OF METAL-ION CHELATES IN VALIDATING BIOLOGICAL MOLECULES AS DRUG TARGETS IN TEST ANIMAL MODELS 7TM PHARMA A/S (DK) 2003-01-09 WO disclosed
US-5969150-A FLUORESCENT COMPOUNDS FOR MEDICAL DIAGNOSIS, DRUGS AND LABELS OR FUNGICIDES AND VIRICIDES THE ROCKEFELLER UNIVERSITY (US) 1999-10-19 US disclosed
US-5064832-A Bipyrimidine Compounds, Antitumor Agents CIBA-GEIGY CORPORATION (US) 1991-11-12 US disclosed
US-4968804-A Bipyridine compounds CIBA-GEIGY CORPORATION (US) 1990-11-06 US disclosed
EP-0350448-A1 Biaryl compounds CIBA-GEIGY AG (CH) 1990-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247818-A1 STEREOSELECTIVE PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES RNGTT, CPSF6, ENDOD1 KDM5C 578/4885KDM4B 544/4885KDM5B 743/4885
US-20230040262-A1 STEREOSELECTIVE PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES RNGTT, CPSF6, RNASEL KDM5C 575/4885KDM4B 549/4885KDM5B 746/4885
US-11286262-B2 Stereoselective process for preparing substituted polycyclic pyridone derivatives RNGTT, CPSF6, ENDOD1 KDM5C 578/4885KDM4B 544/4885KDM5B 743/4885
US-12612415-B2 Stereoselective process for preparing substituted polycyclic pyridone POLR1A, RNASEH1, RNASEL KDM5C 1564/4885KDM4B 1889/4885KDM5B 2119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.